Valtech Cardio will present the first-in-human data for its Cardioband Tricuspid Repair (TR) system at PCR London Valves 2016 (18–20 September, London, UK). Updated two-year follow-up results from the multicentre Cardioband Mitral study will also be presented at the meeting. Furthermore, a Valtech symposium titled—“Cardioband: clinical reality for mitral and tricuspid valve repair”—will be held on 20 September and will be chaired by Eberhard Grube (University of Bonn, Germany) and Karl-Heinz Kuck (Asklepios Klinic St Georg, Hamburg, Germany)
Cardioband TR is designed to enable physicians to reconstruct the tricuspid valve using the same technique and implant as Cardioband mitral valve repair technology. A first-in-human CE study in Europe is now recruiting. Cardioband (mitral) combines a reconstruction implant, similar to surgical annuloplasty devices, with a transfemoral, transseptal delivery system. Connection of the implant to the mitral annulus is sutureless, using specially designed anchors. Reshaping of the mitral annulus to eliminate functional mitral reugitation is done under physiological conditions and echocardiographic guidance for optimal results.
Francesco Maisano (The University Hospital of Zurich, Zurich, Switzerland), who successfully performed the first implantation of Cardioband TR, says: “I am pleased to share my first experience with Cardioband TR, which shows that it is feasible to perform a successful trans venous surgical like annuloplasty procedure for the treatment of tricuspid regurgitation. The device has the potential to reproduce surgical standards, although our experience is still limited at the moment.”
Valtech’s tricuspid and mitral systems will be featured in the following presentations at PCR London Valves:
- Direct annuloplasty—Cardioband in tricuspid regurgitation (by Kuck) as part of the “Innovation in percutaneous tricuspid valve intervention”: 18 September, 3.40—4.35pm (Room 5)
- One year follow-up results of mitral valve transcatheter annuloplasty system for mitral reconstruction multicentre trial (by RS von Bardeleben, University of medicine Mainz, Mainz, Germany) as part of the “Mitral and tricuspid valve interventions”: 19 September, 9.30–10.30am (Room 4)
- Cardioband implantation to treat recurrent mitral regurgitation after MitraClip therapy (by M Taramasso, University Hospital of Zurich, Zurich, Switzerland: 20 September, 11am–12.30pm (Room 5)
In addition to these presentations, attendees of PCR London Valves 2016 can visit Valtech at Booth #7 and learn about Cardioband procedures at the Training Village.
